Impedimed (ASX:IPD) Cash Flow from Financing: A$19.92 Mil (TTM As of Dec. 2025)


What is Impedimed Cash Flow from Financing?

Impedimed ASX:IPD Cash Flow from Financing is A$19.92 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2025, Impedimed paid A$0.00 Mil more to buy back shares than it received from issuing new shares. It received A$7.68 Mil from issuing more debt. It paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received A$0.00 Mil from paying cash dividends to shareholders. It spent A$1.62 Mil on other financial activities. In all, Impedimed earned A$6.05 Mil on financial activities for the six months ended in Dec. 2025.


Impedimed  (ASX:IPD) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Impedimed's issuance of stock for the six months ended in Dec. 2025 was A$0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Impedimed's repurchase of stock for the six months ended in Dec. 2025 was A$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Impedimed's net issuance of debt for the six months ended in Dec. 2025 was A$7.68 Mil. Impedimed received A$7.68 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Impedimed's net issuance of preferred for the six months ended in Dec. 2025 was A$0.00 Mil. Impedimed paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Impedimed's cash flow for dividends for the six months ended in Dec. 2025 was A$0.00 Mil. Impedimed received A$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Impedimed's other financing for the six months ended in Dec. 2025 was A$-1.62 Mil. Impedimed spent A$1.62 Mil on other financial activities.


Impedimed Cash Flow from Financing Related Terms


Impedimed Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Impedimed's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Impedimed Cash Flow from Financing Chart

Impedimed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.47 39.92 27.93 -0.48 13.64

Impedimed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.24 -0.22 13.86 6.05

Impedimed Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Impedimed's Cash from Financing for the fiscal year that ended in Jun. 2025 is calculated as:

Impedimed's Cash from Financing for the quarter that ended in Dec. 2025 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$19.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of A$19.92 Mil mean?
Impedimed (ASX:IPD) has a Cash Flow from Financing of A$19.92 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Impedimed and its competitors.
Is Impedimed's Cash Flow from Financing too high?
Impedimed's current Cash Flow from Financing is A$19.92 Mil.
How does Impedimed's Cash Flow from Financing compare to ABT and SYK?
Impedimed's Cash Flow from Financing of A$19.92 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Impedimed and its competitors. Impedimed's current Cash Flow from Financing is A$19.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 92.5% below its estimated fair value. The current Cash Flow from Financing is A$19.92 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current Cash Flow from Financing is A$19.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Impedimed Business Description

Other Exchanges IPDQF:USA
Address 5900 Pasteur Court, Suite 125, Carlsbad, CA, USA, 92008
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.